Immunization of mice with a synthesized peptide derived from the human KRT15 protein is the first step in the production of the KRT15 monoclonal antibody. B cells isolated from the mouse spleen are fused with myeloma cells to generate hybridomas. Hybridomas are screened to identify those that produce KRT15 antibodies. The chosen hybridomas are cultured in the mouse abdominal cavity, and the KRT15 monoclonal antibodies are purified using affinity chromatography with a specific immunogen. The resulting KRT15 monoclonal antibody is a mouse monoclonal antibody that binds specifically to human KRT15 protein and can be used for ELISA and IHC applications.
KRT15 is a type I intermediate filament protein that is mainly expressed in basal cells of the skin and other stratified epithelia. Its main function is to provide structural support to cells and tissues, and it plays a critical role in maintaining the integrity and strength of the skin. In addition, KRT15 has been implicated in the regulation of cell proliferation, differentiation, and migration, as well as wound healing and tissue repair processes. Mutations in the KRT15 gene have been linked to various skin disorders, including epidermolysis bullosa simplex and other keratinopathies.
